Paradigm Health announced that it has acquired Flatiron Health’s clinical-research business, in a transaction that brings together the largest tech-enabled oncology research network in the United States and a comprehensive suite of clinical-research solutions.
The deal also establishes a multi-year collaboration between the two organizations, creating a united effort to rebuild the clinical-research ecosystem and expand access to clinical trials for patients across the U.S. and globally.
Through the acquisition, Paradigm Health’s network will expand to include more than twenty-five academic medical centers and health systems, and will gain access to nearly one hundred community oncology practices nationwide. This expanded network collectively reaches over 2.4 million patients across the United States. The long-term partnership will integrate Flatiron’s existing clinical-research infrastructure and site network with Paradigm Health’s end-to-end technology platform, enabling more patients to access clinical trials without the need for building costly new infrastructure.
With this expansion, the companies aim to transform how clinical trials are conducted, broadening their reach beyond traditional academic research centers to community-based practices and rural settings. The acquisition strengthens Paradigm Health’s relationships with major biopharma companies. The integration will also add capacity to run pragmatic Phase IV clinical trials embedded within routine care.
By uniting Flatiron’s established community-based oncology research network and Paradigm Health’s AI-powered trial platform, the collaboration is positioned to reduce barriers to trial participation, streamline trial operations, and make clinical research more efficient and representative.
This acquisition marks a major reconfiguration in the U.S. oncology trial landscape. Where historically most clinical trials have been concentrated in large academic centers, the new model seeks to decentralize research and embed it directly into everyday care settings. Under this model, community practices and health systems that use Flatiron’s OncoEMR electronic-health-record platform will be able to avail Paradigm Health’s research support, thus significantly expanding the reach of clinical trials.
Also Read